Inhibiting RIPK1 has shown efficacy in models of NET-driven diseases, including autoimmune vasculitis, venous thrombosis, and Systemic Lupus Erythematosus (SLE) (74). Here, RIPK1 is linked to systemic lupus erythematosus.